We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Your promising new drug is ready for clinical trials, so here is a big question: should you be thinking locally... or globally? According to a recent survey nearly 50% of respondents find the experience of working with their CROs unsatisfactory. Choosing the right CRO can make or break clinical trial success. Irina Petrova MD, OCT Clinical director of clinical operations, will guide you by sharing insights.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
